NASDAQ:IOVA Iovance Biotherapeutics (IOVA) Stock Forecast, Price & News $4.87 -0.17 (-3.37%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$4.81▼$5.1750-Day Range$4.65▼$8.1552-Week Range$4.41▼$10.41Volume8.71 million shsAverage Volume7.91 million shsMarket Capitalization$1.21 billionP/E RatioN/ADividend YieldN/APrice Target$19.54 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Iovance Biotherapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.77 Rating ScoreUpside/Downside301.2% Upside$19.54 Price TargetShort InterestBearish14.72% of Float Sold ShortDividend StrengthN/ASustainability-0.49Upright™ Environmental ScoreNews Sentiment0.33Based on 24 Articles This WeekInsider TradingAcquiring Shares$26.56 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.87) to ($1.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.73 out of 5 starsMedical Sector85th out of 967 stocksBiological Products, Except Diagnostic Industry8th out of 155 stocks 4.4 Analyst's Opinion Consensus RatingIovance Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.54, Iovance Biotherapeutics has a forecasted upside of 301.2% from its current price of $4.87.Amount of Analyst CoverageIovance Biotherapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.72% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Iovance Biotherapeutics has recently increased by 9.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIovance Biotherapeutics has received a 75.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Iovance Biotherapeutics is -0.49. Previous Next 3.0 News and Social Media Coverage News SentimentIovance Biotherapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Iovance Biotherapeutics this week, compared to 4 articles on an average week.Search Interest52 people have searched for IOVA on MarketBeat in the last 30 days. This is an increase of 136% compared to the previous 30 days.MarketBeat Follows30 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 650% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $26,555,600.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.40% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.85% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.87) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Iovance Biotherapeutics (NASDAQ:IOVA) StockIovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Read More IOVA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IOVA Stock News HeadlinesSeptember 22, 2023 | benzinga.comIovance Biotherapeutics Director Makes $55K Stock PurchaseSeptember 20, 2023 | americanbankingnews.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Short Interest UpdateSeptember 23, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 20, 2023 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Trading Down 4.9% Following Analyst DowngradeSeptember 19, 2023 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Price Target Lowered to $18.00 at BarclaysSeptember 19, 2023 | americanbankingnews.comIovance Biotherapeutics Sees Unusually High Options Volume (NASDAQ:IOVA)September 19, 2023 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Sees Unusually-High Trading Volume After Insider Buying ActivitySeptember 18, 2023 | seekingalpha.comIovance Biotherapeutics: Navigates Regulatory Delays With Strategic Finesse (Rating Upgrade)September 23, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.September 18, 2023 | msn.comBarclays Maintains Iovance Biotherapeutics (IOVA) Overweight RecommendationSeptember 18, 2023 | benzinga.comThinking about buying stock in Navios Maritime Holdings, Biodexa Pharmaceuticals, Iovance Biotherapeutics, Neubase Therapeutics, or Iris Energy?September 18, 2023 | msn.comPayPal and Dropbox stocks fall after downgrades, GM shares inch higher, and more stocks on the moveSeptember 18, 2023 | benzinga.comAlteryx, Iovance Biotherapeutics And Other Big Stocks Moving Higher In Monday's Pre-Market SessionSeptember 18, 2023 | finance.yahoo.comIndependent Director of Iovance Biotherapeutics Wayne Rothbaum Buys 28% More SharesSeptember 17, 2023 | americanbankingnews.comIovance Biotherapeutics' (IOVA) "Buy" Rating Reiterated at MizuhoSeptember 17, 2023 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Earns "Buy" Rating from Truist FinancialSeptember 17, 2023 | americanbankingnews.comWayne P. Rothbaum Buys 5,000,000 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) StockSeptember 17, 2023 | americanbankingnews.comIovance Biotherapeutics' (IOVA) Buy Rating Reaffirmed at HC WainwrightSeptember 17, 2023 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Receives Market Outperform Rating from JMP SecuritiesSeptember 17, 2023 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Up on Insider Buying ActivitySeptember 16, 2023 | msn.comBiggest stock movers today: Arm Holdings and Iovance Biotherapeutics and moreSeptember 16, 2023 | msn.comBiggest stock movers today: Arm Holdings and Iovance BiotherapeuticsSeptember 15, 2023 | markets.businessinsider.comPersonalized Skin Cancer Therapy, Despite FDA Delay: Analysts Show Confidence In Iovance Biotherapeutics TherapySeptember 15, 2023 | markets.businessinsider.comIovance Biotherapeutics: FDA Extends PDUFA Date For Iovance BLA On Resource ConstraintsSeptember 15, 2023 | marketwatch.comIovance Biotherapeutics Shares Rise 11% After FDA Agrees to Expedite ReviewSeptember 15, 2023 | msn.comIova stock jumps 15% in wake of FDA update on drug lifileucelSeptember 15, 2023 | finance.yahoo.comIovance (IOVA) Up Despite FDA's Delayed Decision on Melanoma DrugSee More Headlines Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address IOVA Company Calendar Last Earnings8/08/2023Today9/23/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IOVA CUSIPN/A CIK1425205 Webwww.iovance.com Phone(650) 260-7120FaxN/AEmployees503Year Founded2013Price Target and Rating Average Stock Price Forecast$19.54 High Stock Price Forecast$38.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+301.2%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-395,890,000.00 Net MarginsN/A Pretax Margin-176,181.52% Return on Equity-78.33% Return on Assets-60.01% Debt Debt-to-Equity RatioN/A Current Ratio3.10 Quick Ratio2.99 Sales & Book Value Annual Sales$238,000.00 Price / Sales5,070.06 Cash FlowN/A Price / Cash FlowN/A Book Value$2.66 per share Price / Book1.83Miscellaneous Outstanding Shares247,777,000Free Float222,008,000Market Cap$1.21 billion OptionableOptionable Beta0.10 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Frederick G. Vogt Esq. (Age 49)J.D., Ph.D., Interim CEO, Pres, Gen. Counsel & Corp. Sec. Comp: $1.39MMr. Jean-Marc Bellemin M.B.A. (Age 50)CFO, Principal Accounting Officer & Treasurer Comp: $932.2kDr. Igor P. Bilinsky (Age 50)Chief Operating Officer Comp: $932.2kDr. Friedrich Graf Finckenstein M.D. (Age 56)Chief Medical Officer Comp: $1.06MMs. Sara PellegrinoVP of Investor Relations & PRMs. Tracy WintonSr. VP of HRMr. Howard B. Johnson M.B.A. (Age 63)Chief Bus. Officer Mr. James Ziegler M.B.A.Exec. VP of CommercialDr. Raj K. Puri M.D.Ph.D., Exec. VP of Regulatory Strategy & Translational MedicineMr. Brian Shew M.B.A.Sr. VP & Head of Digital and Information TechnologyMore ExecutivesKey CompetitorsVir BiotechnologyNASDAQ:VIRBioCryst PharmaceuticalsNASDAQ:BCRXTwist BioscienceNASDAQ:TWSTPrime MedicineNYSE:PRMEApogee TherapeuticsNASDAQ:APGEView All CompetitorsInsiders & InstitutionsBarclays PLCBought 112,432 shares on 9/21/2023Ownership: 0.214%Merrill A McpeakBought 10,000 shares on 9/18/2023Total: $55,600.00 ($5.56/share)Wayne P RothbaumBought 5,000,000 shares on 9/15/2023Total: $26.50 M ($5.30/share)Perceptive Advisors LLCSold 1,303,325 shares on 8/24/2023Ownership: 5.665%Wolverine Trading LLCBought 10,000 shares on 8/23/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions IOVA Stock - Frequently Asked Questions Should I buy or sell Iovance Biotherapeutics stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IOVA shares. View IOVA analyst ratings or view top-rated stocks. What is Iovance Biotherapeutics' stock price forecast for 2023? 13 Wall Street analysts have issued 1-year price objectives for Iovance Biotherapeutics' shares. Their IOVA share price forecasts range from $6.00 to $38.00. On average, they predict the company's stock price to reach $19.54 in the next twelve months. This suggests a possible upside of 301.2% from the stock's current price. View analysts price targets for IOVA or view top-rated stocks among Wall Street analysts. How have IOVA shares performed in 2023? Iovance Biotherapeutics' stock was trading at $6.39 at the beginning of the year. Since then, IOVA stock has decreased by 23.8% and is now trading at $4.87. View the best growth stocks for 2023 here. Are investors shorting Iovance Biotherapeutics? Iovance Biotherapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 30,070,000 shares, an increase of 9.2% from the August 15th total of 27,530,000 shares. Based on an average daily trading volume, of 4,880,000 shares, the days-to-cover ratio is presently 6.2 days. Approximately 14.7% of the shares of the company are sold short. View Iovance Biotherapeutics' Short Interest. When is Iovance Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our IOVA earnings forecast. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.34. The biotechnology company earned $0.24 million during the quarter, compared to analysts' expectations of $3.91 million. During the same period in the prior year, the firm posted ($0.63) EPS. What ETFs hold Iovance Biotherapeutics' stock? ETFs with the largest weight of Iovance Biotherapeutics (NASDAQ:IOVA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).ARK Genomic Revolution ETF (ARKG). What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX). What is Iovance Biotherapeutics' stock symbol? Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA." Who are Iovance Biotherapeutics' major shareholders? Iovance Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.86%), Perceptive Advisors LLC (5.66%), State Street Corp (5.47%), Point72 Asset Management L.P. (3.14%), Artisan Partners Limited Partnership (1.79%) and Geode Capital Management LLC (1.67%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View institutional ownership trends. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Iovance Biotherapeutics' stock price today? One share of IOVA stock can currently be purchased for approximately $4.87. How much money does Iovance Biotherapeutics make? Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.21 billion and generates $238,000.00 in revenue each year. The biotechnology company earns $-395,890,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis. How many employees does Iovance Biotherapeutics have? The company employs 503 workers across the globe. How can I contact Iovance Biotherapeutics? Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com. This page (NASDAQ:IOVA) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.